MARKETSnap
  • Gainers &
    Losers
  • Most Active &
    More
  • 52-Week
    High/Low
  • P/E
    Ratios
    • Large Caps
    • Absolute
    • Total Market PE
  • Stocks
    Performance
    • Large Caps
    • Absolute
  • Industries
    Performance
    • Industry
    • Sector
  • Dividends
  • 📅 Calendar
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 🔧 Tools
    • 💰 Intrinsic Value Calculator
    • 📈 Compounding Calculator
    • 🤖 Stock Pick Screener
  • More
    • Investment Compounding Calculator
    • Commodities
    • Currencies
    • Economic Indicators
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
4887.T stock logo

4887.T

Sawai Group Holdings Co., Ltd.

$2066
-38.5
 (-1.83%)
[ms_data_label text=’Delayed data’]
Exchange:  JPX
Market Cap:  238.593B
Shares Outstanding:  131.367M
Overview
Earnings
Financials
Valuation
Chart

About The Company

Sector:  Healthcare
Industry:  Drug Manufacturers – Specialty & Generic
   
CEO:  Mitsuo Sawai
Full Time Employees:  3482
Address: 
5-2-30, Miyahara
Osaka
532-0003
JP
Website:  https://www.sawaigroup.holdings
Sawai Group Holdings Co., Ltd., together with subsidiaries, engages in the research, development, manufacturing, and marketing of generic pharmaceutical products primarily in Japan and the United States. It offers generic drugs in various dosage forms, including tablets, oral dispersing tablets, capsules, granules, injectables, tapes, ophthalmic or nasal solutions, syrups, and other forms in the therapeutic areas of cardiovascular, gastro-intestinal, blood/body fluid, other metabolic, antibiotics, central nervous system, antiallergics, urogenital organs and the anus, antineoplastic, vitamins, anti-cancer, chemotherapeutic agents, respiratory organ agents, hormone agents, etc. The company’s products include atorvastatin, limaprost alfadex, lansoprazole, aprepitant, micafungin sodium, silodosin, blonanserin, oseltamivir, capecitabine, atomoxetine hydrochloride, nalfurafine, memantine hydrochloride, eldecalcitol, bazedoxifene, fexofenadine hydrochloride, dutasteride, pregabalin, duloxetine hydrochloride, morphine sulfate tablets, tosymra nasal spray, zembrace symtouch, and ramelteon tablets. It also manufactures and sells medicinal products. The company sells its generic drugs to distributors, retail stores, and other pharmaceutical manufacturers, as well as directly to medical institutions, such as hospitals, general practitioners, and dispensing pharmacies in Japan; and pharmaceutical products to wholesalers in the United States. Sawai Group Holdings Co., Ltd. was founded in 1929 and is headquartered in Osaka, Japan.

Click to read more…

Revenue Segmentation

🔒 You are currently logged out

Login

It’s free

EPS

Historical EPS and analyst estimates in one chart. Log in for the full interactive view and links to detailed estimates.

Log in to continue

Log in for the full EPS chart and links to analyst estimates.

Login — it's free
View full analyst estimates

Earnings Call

No earnings call materials on file for this symbol yet.

Log in to continue

Log in to read the full transcript and AI-generated earnings summaries.

Login — it's free
Income Statement
Balance Sheet
Cash Flow Statement
Analyst Estimates

Income Statement

Year202320242025
Revenue200,344,000176,862,000189,024,000
Gross Profit62,633,00054,319,00056,351,000
EBITDA34,871,00036,875,00019,441,000
Operating Income16,387,00018,886,00020,241,000
Net Income12,667,00013,695,00011,969,000

Log in to continue

Log in to see the income statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Balance Sheet

Year202320242025
Total Assets364,165,000382,024,000354,623,000
Total Liabilities151,425,000163,994,000180,768,000
Total Stockholders Equity201,643,000212,661,000173,854,000
Total Debt77,073,00087,127,00095,107,000
Cash and Cash Equivalents33,076,00026,368,00038,785,000

Log in to continue

Log in to see the balance sheet and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Cash Flow Statement

Year202320242025
Operating Cash Flow13,026,00023,149,00027,851,000
Capital Expenditure-20,727,000-17,915,000-20,567,000
Free Cash Flow-7,701,0005,234,0007,284,000
Net Income11,896,00012,679,0002,173,000
Net Change in Cash-14,641,000-6,708,00012,417,000

Log in to continue

Log in to see the cash flow statement and 10 historical years.

Login — it's free

(* All numbers are in thousands)

Analyst Estimates

Fiscal Year2030Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Low)245,417,211.077Full AccessFull AccessFull AccessFull Access
Estimated Revenue (High)270,053,687.865Full AccessFull AccessFull AccessFull Access
Estimated Revenue (Avg)257,063,000Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Low)28,086,698.767Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (High)30,906,212.929Full AccessFull AccessFull AccessFull Access
Estimated Ebitda (Avg)29,419,497.571Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Low)24,827,218.163Full AccessFull AccessFull AccessFull Access
Estimated Net Income (High)28,114,009.464Full AccessFull AccessFull AccessFull Access
Estimated Net Income (Avg)26,380,901.130Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Low)37,312,953.029Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (High)41,058,654.878Full AccessFull AccessFull AccessFull Access
Estimated SGA Expense (Avg)39,083,565.502Full AccessFull AccessFull AccessFull Access
Estimated EPS (Avg)212.130Full AccessFull AccessFull AccessFull Access
Estimated EPS (High)226.070Full AccessFull AccessFull AccessFull Access
Estimated EPS (Low)199.640Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated Revenue)1Full AccessFull AccessFull AccessFull Access
Number of Analysts (Estimated EPS)1Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in and subscribe to Full Access to see up to 5 years of analyst estimates.

Login — it's free

(* All numbers are in thousands)

Current Key Metrics

?Revenue
 (TTM)
: 
  ?P/S
 (TTM)
: 
1.19
?Net Income
 (TTM)
: 
  ?P/E
 (TTM)
: 
-87.14
?Enterprise Value
 (TTM)
: 
314.959B  ?EV/FCF
 (TTM)
: 
53.87
?Dividend Yield
 (TTM)
: 
0.03  ?Payout Ratio
 (TTM)
: 
-2.28
?ROE
 (TTM)
: 
-0.02  ?ROIC
 (TTM)
: 
0.03
?Net Debt
 (TTM)
: 
  ?Debt/Equity
 (TTM)
: 
0.69
?P/B
 (TTM)
: 
1.33  ?Current Ratio
 (TTM)
: 
2.25

Log in to continue

Log in to see all key valuation metrics and ratios for this symbol.

Login — it's free

Forward P/E Ratios

?

Forward P/E (Avg EPS estimate) — log in with Full Access for high/low estimates and the interactive table.

Forward P/E 1YFull AccessFull AccessFull AccessFull Access
2,560.58Full AccessFull AccessFull AccessFull Access

Log in to continue

Log in with Full Access for forward P/E high/low estimates and the full multi-year table.

Login — it's free

SWOT Analysis

🔒 You are currently logged out

Login

It's free

At what price to buy it? -
Intrinsic Value Calculator

This is an automatic estimate. The most reliable way to know fair value for your own assumptions is to run the calculator below.


Calculate T Intrinsic Value

Common questions about 4887.T valuation

Is Sawai Group Holdings Co., Ltd. (4887.T) overvalued or undervalued right now?

MARKETSnap estimates intrinsic value for Sawai Group Holdings Co., Ltd. (4887.T) using its proprietary valuation methodology, which incorporates discounted cash flow (DCF) analysis together with long-term earnings and fundamentals assumptions. By comparing intrinsic value to the current market price, long-term investors can see whether the stock screens as potentially overvalued, fairly valued, or undervalued today.

Is 4887.T a buy, hold, or sell for long-term investors?

MARKETSnap does not give one-word “buy” or “sell” calls. Instead, it shows whether 4887.T trades at a premium or discount to its estimated intrinsic value, how sensitive that value is to growth and margin assumptions, and how the stock fits into a diversified, long-term portfolio so investors can make their own buy, hold, or sell decision.

What is 4887.T’s P/E ratio?

You can see 4887.T’s trailing P/E (TTM) and forward P/E estimates in the Current Key Metrics and Forward P/E Ratios sections above. The P/E ratio compares the current share price to earnings per share and helps investors gauge valuation relative to earnings.

How is intrinsic value calculated for 4887.T?

MARKETSnap uses its own valuation framework—not a generic spreadsheet DCF alone. Future cash flows and earnings are projected, discounted, and combined with MARKETSnap’s methodology so intrinsic value reflects fundamentals and long-term assumptions. You can run your own inputs and see the result using the Intrinsic Value Calculator above.

Is 4887.T a good long-term investment?

Whether 4887.T fits a long-term portfolio depends on your assumptions about growth, margins, and risk. MARKETSnap provides the metrics, intrinsic value calculator, and SWOT context so you can form your own view rather than rely on a single buy/sell rating.

4887.T

1-day price chart preview. Log in for 1W through 5Y ranges and period tabs.

[ms_data_label text="Daily snapshot"]

-1.83
MARKETSnap

Trading Metrics:

[ms_session_rows_unavailable]
Open: [ms_cell_or_dash table='trading_quote' column='open']   Previous Close: [ms_cell_or_dash table='trading_quote' column='previousClose']
Day Low: [ms_cell_or_dash table='trading_quote' column='dayLow']   Day High: [ms_cell_or_dash table='trading_quote' column='dayHigh']
Year Low: 1650   Year High: 2447
Price Avg 50: 2218.26   Price Avg 200: 2115.12
Volume: 233900   Average Volume: 334791

Log in to continue

Log in for multi-period charts (1W–5Y), period tabs, and the same layout as members.

Login — it's free
See in Nexus

Relevant news

DISCLAIMER: The stock market data provided on this website is for informational purposes only and is not intended for trading purposes. While we strive to provide accurate and timely information, we cannot guarantee that the information is accurate at the moment it is received or that it will continue to be accurate in the future. We are not responsible for any actions taken based on the information provided on this website. Always consult with a licensed financial professional before making any investment decisions.
Terms of Service

Copyright © 2025 MarketSnap. All rights reserved.

Contact Us

Privacy Policy

Cookie Policy

Terms of Service

Hover Image
MARKETSnap

Market

🇺🇸 United States
  • Gainers & Losers
  • Most Active & More
  • 52-Week High/Low
  • Dividends
    • Large Caps
    • Absolute
    • Total Market PE
    • Large Caps
    • Absolute
    • Industry
    • Sector
    • Earnings Calendar
    • Dividends Calendar
    • Economics Calendar
  • 💰 Stock intrinsic value Calculator
  • 📈 Investment Compounding Calculator
  • 🤖 Stock Pick Screener
  • 📋 Watchlist & Portfolio
    • Commodities
    • Currencies
      • Inflation
      • Consumer Sentiment
      • Recession Probability
      • Treasury Rates
      • GDP
  • Nexus
  • Login Login
  • Profile Profile
  • Watchlists Watchlists
  • My Valuations My Valuations
  • Settings Settings

Media

Watch Listen Read